Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levocetirizine oral solution in young children with allergic rhinitis
ChiCTR2200056933Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of levocetirizine in allergic rhinitis (AR), sponsored by Beijing Children's Hospital. Primary endpoints: Adverse events and Allergic Rhinitis Symptom Score. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
levocetirizine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2200056933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056933.